Revenue grew 5% year-over-year to $183.9 million, with improved gross margin and strong cash flow. Key brands showed resilient demand despite pricing and competitive pressures, while new product launches and pipeline progress supported growth. IMS facility remediation and BAQSIMI pricing issues are…
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH)will be reporting results this Thursday after market hours. Here’s what to look for.Amphastar Pharmaceuticals missed analysts’ revenue expectations last quarter, reporting revenues of $171.2 million, flat year on year. It was a disappoint…
Amphastar appointed Anthony Pierce as a Class III director, effective July 9, 2026.Original SEC Filing: Amphastar Pharmaceuticals, Inc. [ AMPH ] - 8-K - Jul. 13, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note thi…
